Cognition Therapeutics, Inc.
NASDAQ:CGTXBiotechnology
-$0.01 today
- Market cap
- $57.06M
- Beta
- 1.75
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$0.22
Volume 0.34M
Average 1.23M
CGTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cognition Therapeutics, Inc.NASDAQ: CGTX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $68K rose 51.1% year over year, ahead of the -0.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at -1.0% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +51.1% holds above the trailing-twelve-month pace of -0.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 228K USD
- Year-over-year change
- -14.3%
- 4-year CAGR
- +25.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 228K | -14.3% |
| FY2024 | 2024-12-31 | 266K | +5.6% |
| FY2023 | 2023-12-31 | 252K | +7.2% |
| FY2022 | 2022-12-31 | 235K | +152.7% |
| FY2021 | 2021-12-31 | 93K | — |
Depreciation & Amortization vs competitors
How CGTX compares with its peers on the latest reported figures
- CGTX's LTM Mar 2026 depreciation & amortization of $251K is the 5th largest of the 8 companies compared; the peer median is $308K.
- Its year-over-year change of -0.8% is the 2nd highest of 8, against a peer median of -44.0%.
- Over three fiscal years its annual growth of -1.0% compares with a peer median of +4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.38M | -44.0% | +24.3% | 6.0% | |
| LTM Mar 2026 | $4.89M | -22.2% | +22.5% | 32.5% | |
| LTM Mar 2026 | $3.84M | -23.0% | -14.6% | 334.6% | |
| LTM Mar 2026 | $308K | -77.1% | -35.0% | 4.1% | |
| LTM Mar 2026 | $251K | -0.8% | -1.0% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +130.4% | +136.6% | 0.4% |
| LTM Mar 2026 | $876 | -75.7% | -21.0% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding CGTX) | $308K | -44.0% | +4.0% | 5.0% | |
Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.72M) | (21.4M) | (25.79M) | (33.97M) | (23.49M) |
| Depreciation & Amortization | 93K | 235K | 252K | 266K | 228K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 3.57M | 4.35M | 3.75M | 2.09M |
| Change in Working Capital | 2.84M | (943K) | 4.85M | 1.29M | (3.46M) |
| Accounts Receivables | (1.11M) | (1.41M) | 2.39M | (1.41M) | (7.24M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.17M | (1.09M) | 0 | 0 | 3.51M |
| Other Working Capital | 1.79M | 1.56M | 2.46M | 2.69M | 270K |
| Other Non-Cash Items | (33K) | 0 | 318K | 195K | 41K |
| Operating Cash Flow | (3.63M) | (18.53M) | (16.02M) | (28.47M) | (24.59M) |
| Capital Expenditures | (27K) | (171K) | (147K) | (4K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 9K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (27K) | (171K) | (147K) | (4K) | 9K |
| Debt Repayment | (268K) | (1.4M) | (811K) | (739K) | (353K) |
| Common Stock Issued | 44.22M | 5.32M | 5.33M | 24.35M | 37.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.25M | 1.62M | 0 | (46K) | (164K) |
| Financing Cash Flow | 53.2M | 5.55M | 4.52M | 23.57M | 36.57M |
| Effect of Forex Changes | (11K) | (1K) | 4K | 0 | 0 |
| Net Change in Cash | 49.53M | (13.16M) | (11.64M) | (4.91M) | 11.99M |
| Free Cash Flow | (3.66M) | (18.7M) | (16.17M) | (28.48M) | (24.59M) |
Cognition Therapeutics, Inc.
NASDAQ:CGTX
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.